



September 2007

Does 'excessive' anticoagulation predispose to periprosthetic infection?

Javad Parvizi

Thomas Jefferson University and Rothman Institute of Orthopedics, parvj@aol.com

Elie Ghanem

Thomas Jefferson University and Rothman Institute of Orthopedics, elieghanem@gmail.com

Ashish Joshi

Thomas Jefferson University and Rothman Institute of Orthopedics

Peter F. Sharkey

Thomas Jefferson University and Rothman Institute of Orthopedics

William J. Hozack

Thomas Jefferson University and Rothman Institute of Orthopedics

See next page for additional authors

[Let us know how access to this document benefits you](#)

Follow this and additional works at: <http://jdc.jefferson.edu/orthofp>

 Part of the [Orthopedics Commons](#)

Recommended Citation

Parvizi, Javad; Ghanem, Elie; Joshi, Ashish; Sharkey, Peter F.; Hozack, William J.; and Rothman, Richard H., "Does 'excessive' anticoagulation predispose to periprosthetic infection?" (2007). *Department of Orthopaedic Surgery Faculty Papers*. Paper 8.
<http://jdc.jefferson.edu/orthofp/8>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Orthopaedic Surgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Javad Parvizi, Elie Ghanem, Ashish Joshi, Peter F. Sharkey, William J. Hozack, and Richard H. Rothman

1 **Does ‘Excessive’ Anticoagulation Predispose to Periprosthetic Infection?**

2

3

4 Javad Parvizi MD, FRCS, Elie Ghanem MD, Ashish Joshi MD, Peter F Sharkey MD,

5 William J Hozack MD, Richard H Rothman MD, PhD

6

7

8

9

10

11

12 Investigations were performed at the Rothman Institute of Orthopedics, Thomas Jefferson

13 University, Philadelphia, PA 19107

14

15

16

17

18

19 Correspondence to: Javad Parvizi, MD, FRCS, Rothman Institute of Orthopedics at

20 Jefferson, 925 Chestnut Street, Philadelphia PA 19107.

21 Phone: 267-399-3617; Fax: 215-503-0580,

22 E-mail: parvj@aol.com

23

1 **Abstract**

2 **Background:** Although persistent drainage and hematoma formation are recognized risk
3 factors for development of periprosthetic infection, it is not known that excess
4 anticoagulation is a predisposing factor.

5 **Methods:** We conducted a 2 to 1 case-control study with 78 cases that underwent
6 revision for septic failure. The controls underwent the same index procedure but did not
7 develop consequent infection. Patient co-morbidities, medications, intraoperative, and
8 postoperative factors were compared.

9 **Results:** Postoperative wound complications including development of hematoma and
10 wound drainage were significant risk factors for periprosthetic infection. A mean INR
11 >1.5 was found to be more prevalent in patients who developed of postoperative wound
12 complications and subsequent periprosthetic infection.

13 **Conclusions:** Cautious anticoagulation to prevent hematoma formation and/or wound
14 drainage is critical to prevent periprosthetic infection and its undesirable consequences.

15

16

17

18

19

20

21

22

23

1 **Introduction**

2 Despite immense improvements in prevention and treatment, the management of
3 periprosthetic infection continues to be challenging¹⁻⁴. The incidence of periprosthetic
4 infection after primary arthroplasty is less than 1%⁵ and up to 7%^{6,7} after revision joint
5 arthroplasty. Numerous risk factors for periprosthetic infection have been identified^{8,9}.
6 Immunocompromised status of the patient, skin lesions such as psoriatic plaques, and
7 problems related to wound healing are some of the predisposing factors for periprosthetic
8 infection following total joint arthroplasty¹⁰⁻¹³.

9 In a previous case-controlled study, patients with delayed wound discharge,
10 wound dehiscence and hematoma formation were found to have a higher incidence of
11 periprosthetic infection⁸. Although the latter finding appears intuitive, the exact etiology
12 of wound problems following joint arthroplasty was not elucidated in the stated study⁸.

13 We hypothesized that patients receiving ‘excessive’ anticoagulation, defined as
14 International Randomized Ration (INR) greater than clinically intended level, may be at
15 risk of developing wound related problems which in turn predisposed them to
16 periprosthetic infection. This case-control study was conceived to examine the correlation
17 between anticoagulation and periprosthetic infection.

18

19 **Materials and Methods**

20 **Study Group**

21 Institutional review board approval was obtained prior to initiation of this case-
22 control study. The cohort consisted of all patients who underwent primary or revision
23 total knee or total hip arthroplasty for an aseptic diagnosis during the period of 2000 to

1 2005 and developed subsequent periprosthetic infection. The diagnosis of periprosthetic
2 infection was reached on the basis of patients having at least three out of five of the
3 following criteria: 1) abnormal serology (ESR >30 mm/hr; CRP >1mg/dl), 2) strong
4 clinical and radiographic suspicion for periprosthetic infection, 3) positive joint aspiration
5 culture, 4) evidence of purulence during the subsequent surgical intervention, and 5)
6 positive intraoperative culture¹⁴. The patients with periprosthetic infection were then
7 closely matched in a 2:1 ratio with those undergoing the same procedure who did not
8 develop periprosthetic infection following their index surgery. The matching criteria
9 included the underlying diagnosis, the type of prosthesis, mode of fixation, surgeon,
10 height, weight, age, gender, and the year of surgery.

11 A thorough review of the medical records was performed to extract the relevant
12 information, which included socio-demographic factors such as age, gender, body mass
13 index, alcohol abuse and smoking habits. Information was also gathered regarding the
14 medication history with special emphasis on steroid therapy and insulin requirement.
15 Detailed information about the patient's medical history including inflammatory
16 arthropathy, autoimmune disease, diabetes mellitus, malignancy, and any other
17 concomitant medical conditions were gathered. A history of septic arthritis of the native
18 joint or any other infection was considered relevant to our analysis. The postoperative
19 course, and in particular the details of anticoagulation and the level of INR, for all these
20 patients following their index primary arthroplasty was recorded. Detailed data regarding
21 the intraoperative and postoperative course of these patients related to their index surgery
22 was also collected which also included the National Nosocomial Infections Surveillance
23 (NNIS) surgical index score¹⁵. The NNIS collates information on the comorbidities,

1 operative time, and the surgical wound classification and has been shown to be an
2 important confounder for periprosthetic infection⁸. We documented the type, time of
3 administration, and duration of prophylactic antibiotic that was given to the patients
4 during the index arthroplasty. All intraoperative and postoperative transfusions of
5 autologous or allogenic nature were also recorded.

6 **Socio-demographics**

7 The infected group included 42 males (54%) and 36 females (46%). Fifty-six
8 percent of the cases and 51% of the controls were considered obese at the time of index
9 surgery (BMI >30 Kg/m²). There was no significant difference in the mean BMI,
10 smoking habit, and alcohol abuse between the cases and the controls (Table1).

11 **Postoperative Protocols**

12 All patients at our institution undergoing joint arthroplasty are placed on low dose
13 warfarin (goal INR= 1.5) unless indicated otherwise. Warfarin is administered on the day
14 of surgery and continued for a period of six weeks. Deviations from the latter occurred if:
15 a) the patient was on anticoagulation prior to the surgery for conditions such as
16 arrhythmia or replaced heart valve, b) had known allergy to warfarin, or c) developed
17 thromboembolism in the postoperative period. In the latter three categories of patients
18 subcutaneous and/or intravenous heparin was used as the sole or the bridging agent until
19 adequate and full anticoagulation (goal INR=2-3) with the oral agent could be
20 established.

21 Prophylaxis for infection using cephalosporin antibiotics (Ancef, 1 gram) or an
22 alternative antibiotic for patients with penicillin allergy is also administered within 60
23 minutes of arthroplasty procedure and continued for 24 hours postoperatively. Antibiotic

1 was administered at a mean of 39 minutes (range, 0-60 minutes) prior to incision among
2 the cases and controls respectively. Cephalosporin was the most frequently administered
3 antibiotic in both groups [cases (72%); controls (88%)] followed by vancomycin [cases
4 (18%); controls (8%)].

5 The wound management consisted of application of a sterile dressing that was
6 placed over the wound in the operating room and usually kept for 24 hours. The wound
7 was then inspected and covered by dry gauze that was changed at least twice daily during
8 the hospital stay. The wound was monitored by the patient and/or the visiting nurses after
9 discharge from hospital. Fluid discharge from the wound beyond postoperative day 7 was
10 deemed clinically significant and abnormal.

11 **Surgical Data**

12 Degenerative joint arthritis was the most common diagnosis in both groups. Other
13 diagnoses included post-traumatic arthritis (4 cases), and inflammatory arthropathy (two
14 cases). Among the 78 patients in the infected group, 43 had undergone total knee
15 arthroplasty (33 primary and 10 revisions), and 35 patients received total hip arthroplasty
16 (12 primary and 23 revisions). The mean duration between index joint arthroplasty and
17 the development of infection was 256 days (range, 4-1890 days). Gram-positive cocci
18 were the most common infecting organisms including *Staphylococcus* coagulase negative
19 (26%), *Staphylococcus aureus* (16%), Methicillin resistant *Staphylococcus aureus*
20 [MRSA] (14%), and other *Streptococcus* species (13%).

21 ***Statistical Analysis***

22 We performed descriptive statistics using SAS version 9.1 to determine the
23 means, standard deviations, and the frequency distribution of the various variables

1 described above. The NNIS index score was stratified into two categories including 0 and
2 greater than or equal to one. Unadjusted analysis was performed using Wilcoxon
3 procedure to compare the means across the continuous variables among the cases and
4 controls. Fisher exact test was used to compare the proportions across the categorical
5 variables in the cases and controls. We analyzed continuous variables using t-statistics,
6 while Chi-Square analysis was used for categorical variables. A p-value of <0.05
7 depicted statistical significance. Adjusted analysis was performed using multivariate
8 stepwise logistic regression to determine the variables predicting infection in this study
9 population.

10 **Results:**

11 **Postoperative Course**

12 Patients who subsequently developed infection had a more protracted
13 hospitalization course with two times the number of postoperative complications
14 (p=0.02) following their index arthroplasty compared to the control patients (Table 1).
15 The mean hospital length of stay in the 78 patients with subsequent periprosthetic
16 infection was significantly longer at 6 days (range, 1-11 days) compared to 4 days (range,
17 2-6 days) in the group of 156 patients without infection (p<0.006). Infected patients were
18 12.6 times more likely to develop hematoma compared to their respective controls and
19 16.8 times more likely to have persistent wound drainage. Although the cases had only
20 slightly higher intraoperative blood loss, they had significantly higher postoperative
21 transfusions compared to control patients (Table1). Wound dehiscence developed
22 following the index arthroplasty in two patients both of whom later developed infection.

1 There was a significantly higher number of reoperations following the index
2 surgery in the group of patients who later became infected (total of 14 reoperations)
3 compared to the control patients (total of 3 reoperations) (OR=11.2, $p<0.0001$). The
4 indication for reoperation included evacuation of hematoma (9 patients), debridement and
5 wash out of draining wound (3 patients), and debridement and closure for wound
6 dehiscence (2 patients) in the infection group. Among the controls, only two patients
7 underwent evacuation of hematoma, while one was reoperated for delayed wound
8 healing.

9 **Stratified Analysis For Anticoagulation**

10 Although the mean INR at all time points was higher in the cohort of patients who
11 developed periprosthetic infection compared to those who did not develop infection, this
12 difference was not found to be statistically different ($p=0.06$). However, the INR level
13 was statistically higher in patients with wound related problems who later developed
14 infection compared to patients who did not develop infection ($p=0.03$). In addition, a
15 significantly greater percentage of infected patients (17%) had an INR level >1.5 at
16 hospital discharge compared to the control group (8%) (Chi-Sq=4.39; $p=0.04$) (Figure 1).
17 Similarly, there were twice as many infected patients (21%) with a mean INR > 1.5
18 compared to the control group (11%) (Chi-Sq=3.97; $p=0.05$) (Figure 1). An INR >1.5 at
19 day of discharge was more prevalent in the group with wound complications (22%)
20 compared to patients with uncomplicated postoperative course with regard to wound
21 healing (8%) ($p=0.005$).

22 There were 13 patients in the periprosthetic infection cohort who had received
23 injectable anticoagulant in addition to or in lieu of oral anticoagulation in the

1 postoperative period that included subcutaneous low-molecular weight heparin (1 case),
2 and intravenous heparin (12 cases). Heparin was administered as prophylaxis for cardiac
3 conditions (arrhythmia and prosthetic heart valves). No patient in this cohort developed
4 pulmonary embolus. Out of the 13 cases that were heparinized, nine patients developed
5 postoperative wound complications including hematoma (3), persistent wound drainage
6 (5), and delayed wound healing (1).

7 **Multivariate Analysis**

8 A multiple logistic regression analysis was performed after adjusting for the
9 various variables. Concomitant comorbidities as measured by ASA (OR=2.07; 95% CI
10 1.08-.97; p=0.03), postoperative transfusions (OR=1.63; 95% CI 1.14-2.33; p=0.007),
11 postoperative wound complications including development of hematoma (OR=27.02;
12 95% CI 11.04-91.59; p=0.0002) and wound drainage (OR=32.20; 95% CI 8.7-119.17;
13 p<0.0001) were significant risk factors for periprosthetic infection.

14

15 **Discussion**

16 Total joint arthroplasty is a successful surgical procedure that continues to confer
17 functional improvement and alleviation of pain for majority of patients with disabling
18 arthritis¹⁶⁻¹⁹. The outcome of this otherwise successful operation is occasionally
19 compromised by complications such as periprosthetic infection²⁰⁻²².

20 Although implementation of strategies such as clean air operating room,
21 administration of perioperative antibiotics, and body exhaust systems have all contributed
22 to prevention of this dreaded complication, periprosthetic infection still continues to
23 occur after total joint arthroplasty^{4,5,7}. A recent study from the Mayo Clinic found that

1 periprosthetic infection has become one of the major causes of failure of total knee
2 arthroplasty²³. The findings of the latter study are truly concerning and raise the question
3 as to why the incidence of periprosthetic infection may be on the rise. The other pertinent
4 and inter-related issue is the identification of factors that predispose the patients to
5 periprosthetic infection.

6 There is a multitude of reasons that may explain the development of infection
7 following joint arthroplasty in general and the increase in the incidence of this
8 complication in particular. First, it may relate to the fact that joint arthroplasty is
9 currently performed in a wide spectrum of patients including immunocompromised
10 patients with concomitant comorbidities such as diabetes, malignancy, and steroid use,
11 which have all been identified as important predisposing factors for periprosthetic
12 infection⁸. Second, improvements in prosthetic design and surgical techniques may have
13 reduced the incidence of mechanical complications, bringing infection to the forefront of
14 major complications. There may be other explanations also¹⁰. Based on our anecdotal
15 observation, we believed that patients receiving ‘excessive’ anticoagulation such as
16 intravenous heparin or high dose oral anticoagulant agents during the postoperative
17 period were at high risk of developing wound related problems that could have in turn
18 resulted in subsequent periprosthetic infection. This study confirmed the latter and
19 revealed some important findings.

20 The incidence of periprosthetic infection was found to be significantly higher in the
21 group of patients who had a protracted postoperative course related to wound problems.
22 The latter is intuitive and has in fact been previously reported⁸. The study, however, did
23 reveal that there was a direct correlation between ‘excessive’ anticoagulation and

1 development of wound related problems that lead to development of subsequent
2 periprosthetic infection. Excessive anticoagulation was either as a result of administration
3 of intravenous agents such as heparin to prevent important and potentially life threatening
4 complications or it resulted from administration of oral agents (warfarin in this case) at a
5 level that was higher than clinically intended.

6 The finding that wound complications and subsequent deep infection are associated
7 with 'excessive' anticoagulation is important and at the same time worrisome. Recent
8 recommendations of American College of Chest Physicians (ACCP) explicitly state that
9 only agents with proven efficacy should be utilized as prophylaxis against
10 thromboembolic disease following total joint arthroplasty²⁴. The criteria set forth by the
11 ACCP, do not recognize low dose warfarin as an effective agent and recommend a higher
12 level of INR (2 to 2.5). The recommendation also endorses low molecular weight heparin
13 as an effective agent. The major concern posed by the orthopedic community with regard
14 to the recommendations of the ACCP relates to the potential for development of wound
15 related problems such as hematoma and wound drainage that may ensue after aggressive
16 anticoagulation regimen. The current study confirms that such problems do occur even
17 after administration of low dose warfarin. Hence, wound related problems and
18 subsequent infection is likely to be more prevalent after higher doses of anticoagulants or
19 injectable agents, as the incidence of bleeding, persistent wound drainage, and hematoma
20 formation has been shown to be higher with injectable agents compared to oral
21 anticoagulants^{25,26}. A previous study has also demonstrated that patients receiving
22 intravenous heparin in the postoperative period were more likely to suffer medical and
23 orthopedic complication²⁷. The latter study did not however find a correlation between

1 anticoagulation and implant related infection. Our study, for the first time to our
2 knowledge, demonstrates a direct correlation between administration of excessive
3 anticoagulation and the development of periprosthetic infection.

4 The findings of this study need to be interpreted with some caveat in mind. This is a
5 retrospective study with all the innate limitations of such a study design with regard to
6 uniformity of data collection. Second, it is possible that factors other than excessive
7 anticoagulation may have lead to the development of periprosthetic infection in this
8 cohort. This study sought to collect information on all predisposing factors that could
9 possibly contribute to the development of periprosthetic infection. One of those may have
10 been the presence of concomitant comorbidities such as diabetes or steroid use. Although
11 the ASA score was higher in the infected group, there did not seem to be a difference in
12 the prevalence of diabetes or other 'predisposing conditions' between the two groups.
13 The only exception is that a higher number of patients in the infected group were
14 receiving oral steroid, as treatment for pulmonary conditions, than the control group. This
15 difference could plausibly be an important confounding variable. There was also a
16 significant difference in the ASA score between the two groups. This could however be
17 explained by the higher incidence of cardiorespiratory conditions among the infected
18 cohort which in turn lead to more of these patients requiring intravenous anticoagulation.
19 More patients in the infected cohort required allogenic transfusion in the postoperative
20 period. Although allogenic transfusion by the virtue of immunomodulation²⁸ can
21 potentially predispose patients to a higher incidence of infection, this correlation has not
22 been proven. Instead we believe the higher need for transfusion in the infected cohort is

1 the reflection of the problem with bleeding, hematoma formation, and persistent wound
2 discharge which in turn lead to the need for reoperation and further blood loss.

3 Despite all the aforementioned limitations, this study serves to highlight an important,
4 and in our opinion a critical, fact. There needs to be an acceptable balance between
5 efforts to prevent thromboembolism and the potential for causing serious harm to patients
6 undergoing total joint arthroplasty. With the continuing improvements in surgical and
7 anesthesia techniques allowing earlier rehabilitation and faster recovery leading to a
8 reduced potential for development of thromboembolism, the benefits of aggressive
9 prophylactic anticoagulation should be weighed against the rising problem of
10 periprosthetic infection.

1 **Legends:**

2 **Figure 1:** The mean International Normalized Ratio (INR) for patients which developed
3 periprosthetic infection (experimental group) compared to those who did not develop
4 infection (control group).

5 **Table 1:** Details of Various Parameters in the Cohort

6 Abbreviations: BMI = Body Mass Index; ASA = American Society of Anesthesiologists;
7 NNIS = National Nosocomial Infection Surveillance; PE= Pulmonary Embolus; DVT=
8 Deep Vein Thrombosis; UTI= Urinary Tract Infection

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

References

- 1
2
3 1. Bauer TW, Parvizi J, Kobayashi N, Krebs V. Diagnosis of periprosthetic infection.
4 *J Bone Joint Surg Am.* 2006;88:869-82.
- 5 2. Toms AD, Davidson D, Masri BA, Duncan CP. The management of peri-prosthetic
6 infection in total joint arthroplasty. *J Bone Joint Surg Br.* 2006;88:149-55.
- 7 3. Leone JM, Hanssen AD. Management of infection at the site of a total knee
8 arthroplasty. *J Bone Joint Surg Am.* 2005;87:2335-48.
- 9 4. Garvin KL, Hanssen AD. Infection after total hip arthroplasty. Past, present, and
10 future. *J Bone Joint Surg Am.* 1995;77:1576-88.
- 11 5. Phillips JE, Crane TP, Noy M, Elliott TS, Grimer RJ. The incidence of deep
12 prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective
13 survey. *J Bone Joint Surg Br.* 2006;88:943-8.
- 14 6. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total
15 hip or knee arthroplasty. *Instr Course Lect.* 1999;48:111-22.
- 16 7. Clohisy JC, Calvert G, Tull F, McDonald D, Maloney WJ. Reasons for revision hip
17 surgery: a retrospective review. *Clin Orthop Relat Res.* 2004;188-92.
- 18 8. Berbari EF, Hanssen AD, Duffy MC, Steckelberg JM, Ilstrup DM, Harmsen WS,
19 Osmon DR. Risk factors for prosthetic joint infection: case-control study. *Clin*
20 *Infect Dis.* 1998;27:1247-54.
- 21 9. Saleh K, Olson M, Resig S, Bershadsky B, Kuskowski M, Gioe T, Robinson H,
22 Schmidt R, McElfresh E. Predictors of wound infection in hip and knee joint
23 replacement: results from a 20 year surveillance program. *J Orthop Res.*
24 2002;20:506-15.
- 25 10. Minnema B, Vearncombe M, Augustin A, Gollish J, Simor AE. Risk factors for
26 surgical-site infection following primary total knee arthroplasty. *Infect Control*
27 *Hosp Epidemiol.* 2004;25:477-80.
- 28 11. Drancourt M, Argenson JN, Tissot DH, Aubaniac JM, Raoult D. Psoriasis is a risk
29 factor for hip-prosthesis infection. *Eur J Epidemiol.* 1997;13:205-7.

- 1 12. Gordon SM, Culver DH, Simmons BP, Jarvis WR. Risk factors for wound
2 infections after total knee arthroplasty. *Am J Epidemiol.* 1990;131:905-16.
- 3 13. Luessenhop CP, Higgins LD, Brause BD, Ranawat CS. Multiple prosthetic
4 infections after total joint arthroplasty. Risk factor analysis. *J Arthroplasty.*
5 1996;11:862-8.
- 6 14. Trampuz A, Hanssen AD, Osmon DR, Mandrekar J, Steckelberg JM, Patel R.
7 Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee
8 infection. *Am J Med.* 2004;117:556-62.
- 9 15. National Nosocomial Infections Surveillance (NNIS) report, data summary from
10 October 1986-April 1996, issued May 1996. A report from the National
11 Nosocomial Infections Surveillance (NNIS) System. *Am J Infect Control.*
12 1996;24:380-8.
- 13 16. Lavernia C, D'apuzzo M, Hernandez VH, Lee DJ. Patient-perceived outcomes in
14 thigh pain after primary arthroplasty of the hip. *Clin Orthop Relat Res.*
15 2005;441:268-73.
- 16 17. Lavernia CJ, Guzman JF, Gachupin-Garcia A. Cost effectiveness and quality of life
17 in knee arthroplasty. *Clin Orthop Relat Res.* 1997;134-9.
- 18 18. Jones CA, Beaupre LA, Johnston DW, Suarez-Almazor ME. Total joint
19 arthroplasties: current concepts of patient outcomes after surgery. *Clin Geriatr Med.*
20 2005;21:527-41, vi.
- 21 19. Tate D, Jr., Sculco TP. Advances in total hip arthroplasty. *Am J Orthop.*
22 1998;27:274-82.
- 23 20. Barrack RL, Engh G, Rorabeck C, Sawhney J, Woolfrey M. Patient satisfaction and
24 outcome after septic versus aseptic revision total knee arthroplasty. *J Arthroplasty.*
25 2000;15:990-3.
- 26 21. Freeman MA, Sudlow RA, Casewell MW, Radcliff SS. The management of
27 infected total knee replacements. *J Bone Joint Surg Br.* 1985;67:764-8.
- 28 22. Wang CJ, Huang TW, Wang JW, Chen HS. The often poor clinical outcome of
29 infected total knee arthroplasty. *J Arthroplasty.* 2002;17:608-14.

1 23. Vessely MB, Whaley AL, Harmsen WS, Schleck CD, Berry DJ. The Chitranjan
2 Ranawat Award: Long-term survivorship and failure modes of 1000 cemented
3 condylar total knee arthroplasties. *Clin Orthop Relat Res.* 2006;452:28-34.

4 24. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG.
5 Prevention of venous thromboembolism: the Seventh ACCP Conference on
6 Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126:338S-400S.

7 25. Colwell CW, Jr., Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S,
8 Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of
9 venous thromboembolic disease after total hip arthroplasty. Evaluation during
10 hospitalization and three months after discharge. *J Bone Joint Surg Am.*
11 1999;81:932-40.

12 26. Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL,
13 O'Connell MB, Ohar JA, Young TR. Prevention of venous thromboembolic disease
14 following primary total knee arthroplasty. A randomized, multicenter, open-label,
15 parallel-group comparison of enoxaparin and warfarin. *J Bone Joint Surg Am.*
16 2001;83-A:900-6.

17 27. Lawton RL, Morrey BF. The use of heparin in patients in whom a pulmonary
18 embolism is suspected after total hip arthroplasty. *J Bone Joint Surg Am.*
19 1999;81:1063-72.

20 28. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and
21 immunomodulation in the critically ill. *Chest.* 2005;127:295-307.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38




Figure1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1
2
3
4
5

Variables	Cases N=78	Controls N=156	p-value
<u>Socio-Demographics</u>			
Age in Years(Mean ± SD)	66 ± 10	66 ± 10	0.91
BMI Kg/m ² (Mean ± SD)	32 ± 9	32 ± 7	0.76
<i>Alcohol Abuse</i>	1 (1%)	0%	0.16
<i>Heavy Smoker</i>	6 (8%)	15 (10%)	0.63
<u>Comorbidities</u>			
ASA score (Mean ± SD)	2.6 ± 0.57	2.4 ± 0.56	0.01
Diabetes mellitus	14 (18%)	22 (14%)	0.56
≥3 co-morbidities	33 (42%)	56 (36%)	0.39
Steroid Therapy	8 (10%)	5 (3%)	0.03
Insulin use	2 (3%)	3 (2%)	0.75
NNIS ≥1	50 (64%)	73 (47%)	0.01
<u>Surgical Data</u>			
Blood loss (Mean ± SD)	354 ± 602	270 ± 341	0.17
Operative time (Mean ± SD)	114 ± 49	114 ± 91	0.97
Total Transfusion (Mean ± SD)	0.78 ± 1.15	0.39 ± 0.79	0.002
Allogenic Transfusion	10 (13%)	3 (2%)	0.0006
Autologous Transfusion	47 (60%)	111 (71%)	0.09
<u>Postoperative Complications</u>			
Wound Hematoma	11 (14%)	2 (1%)	0.0001
Wound Drainage	24 (31%)	4 (3%)	0.0001
Other complications(PE,DVT,UTI)	18 (23%)	18 (12%)	0.02

6
7
8
9
10
11

Table1